AUSTIN, Texas, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced it has been selected by the Advanced Research Projects Agency for Health (ARPA-H) as an awardee of the Sprint for Women’s Health to address critical unmet challenges in women’s health, champion transformative innovations, and tackle health conditions that uniquely or disproportio ...

AUSTIN, Texas, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today announced that it has received approval from the New York State Department of Health’s (NYSDOH) Clinical Laboratory Evaluation Program (CLEP) for OvaWatch®, the Company’s non-invasive blood test for the assessment of ovarian cancer risk for women with an adnexal mass determined by initial ...

Annex Insurance (AWH, Financial) stock recently experienced a sharp decline, dropping 7.47% to $0.761 per share. The trading volume stood at 16,266 shares, with a turnover rate of 0.10% and a price fluctuation of 2.62%.Recent financial reports show Annex Insurance faced significant challenges, recording a revenue of $2.42 million but a net loss of $3.53 million. Earnings per share were reported at -$0.28, with a gross profit of $1.42 million and a negative price-to-earnings ratio of -0.58. Currently, no ins ...

Aspira Womens Health (AWH, Financial) experienced a significant stock price drop of 7.80%, reaching $0.775 per share. The trading volume stood at 14,064 shares with a turnover rate of 0.09% and a volatility of 7.47%.Recent financial results for Aspira Womens Health revealed an operating revenue of $2.42 million and a net loss of $3.53 million, resulting in an earnings per share (EPS) of -$0.28. The gross profit was recorded at $1.42 million, with a price-to-earnings ratio of -0.57. Currently, no institution ...

Core Insights - Aspira Women's Health Inc. has entered a strategic partnership with Dorsata to develop a custom protocol workflow tool aimed at improving the management of adnexal masses [1][2] - The partnership seeks to standardize care and enhance patient outcomes by addressing the challenges in diagnosing and treating adnexal masses, which include ovarian cysts and other growths [2][3] - The integration of the new Module into Dorsata's electronic medical records system is expected to streamline diagnosis and treatment processes while aggregating clinical data for better analysis and outcomes [3] Company Developments - The Module's deployment is anticipated to begin by late 2024, marking a significant advancement in clinical practices for women's health [1] - Aspira's collaboration with over 250 obstetrics and gynecology physicians aims to ensure consistent care across various healthcare settings [2] - The partnership is expected to refine diagnostic and treatment protocols, potentially leading to early identification of ovarian cancer risks [3] Market Outlook - The global ovarian cancer treatment market is projected to grow from $2.50 billion in 2023 to $5.45 billion by 2033, reflecting an 8.10% CAGR [4][5] - Innovations in treatment, such as PARP inhibitors and anti-angiogenic therapies, are expected to enhance efficacy and drive market expansion [4][5] Share Performance - Aspira's shares have decreased by 74.8% year to date, contrasting with a 10% growth in the industry [6] - The company currently holds a Zacks Rank of 3 (Hold), indicating a cautious outlook compared to better-ranked stocks in the medical sector [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------|-------------------------------------------| | | | | For the transition | ______ | | Commission | 001-34810 | | As ...

Financial Data and Key Metrics Changes - OvaSuite revenue for Q2 2024 was $2.4 million, a 13% sequential increase from Q1 and flat compared to Q2 2023 [20] - Total product volume in Q2 reached 6,471, an 11% sequential increase and a 3% year-over-year increase [20] - Average unit price (AUP) for the quarter was $374, slightly up from $369 in Q1 but down 5% from $396 in Q2 2023 [20][21] - Gross margin decreased to 59% from 62% year-over-year due to increased product costs [21] Business Line Data and Key Metrics Changes - OvaWatch test volume increased 24% sequentially and 48% year-over-year, significantly contributing to overall growth [20] - The total addressable market for OvaSuite tests is now estimated to be between 2 to 4 million tests per year, a tenfold increase from previous estimates [6][9] Market Data and Key Metrics Changes - The company has expanded its coverage and reimbursement for OvaSuite products, contracting with Anthem plans and adding several Blue Cross Blue Shield plans [10][11] - The number of states covering OvaSuite tests has increased to nine, including key states like California, New York, and Illinois [11] Company Strategy and Development Direction - The primary focus is to drive adoption of the OvaSuite test portfolio as the universal standard of care for women diagnosed with adnexal masses [10] - The company is enhancing its commercial organization to be more efficient and cost-effective, which is critical for cost containment goals [8] - Ongoing product development includes the EndoCheck test and OvaMDx, with a focus on improving sensitivity for early-stage ovarian cancer [15][17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, highlighting the positive reception of new data and the potential for rapid growth in OvaWatch adoption [39] - The company is actively pursuing non-dilutive funding opportunities and has made significant progress in monetizing its biobank [19][49] - Management aims to continue reducing cash burn while investing in strategic initiatives [51] Other Important Information - The company appointed John Kallassy as Interim Chief Financial Officer, effective August 15, 2024 [26][27] - Management has opted for a 20% reduction in cash-based salary in exchange for additional equity, reflecting confidence in the company's potential [25] Q&A Session Summary Question: Growth between existing customers and new providers - Management indicated growth has been consistent across both existing and new providers [29] Question: FDA approval plans for OvaWatch - The company is currently holding off on FDA approval to accumulate more clinical utility data [32] Question: Physician enthusiasm for OvaWatch - Feedback has been positive, especially regarding its utility for premenopausal and asymptomatic women [39] Question: Next steps for OvaSuite enhancements - The focus is on adoption and potential enhancements, including the EndoCheck score [42] Question: Clinical utility study for OvaWatch - The first phase involves gathering insights from payers about clinical data gaps [46] Question: Non-dilutive financing and balance sheet sustainability - The company is exploring monetization of assets and applying for grants to improve its financial position [49]

Aspira (AWH) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.28 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this diagnostic and bio-analytical company would post a loss of $0.36 per share when it actually produced a loss of $0.39, delivering a surprise of -8.33%.Over the last four quarters, the ...

Aspira Women's Health Reports Second Quarter 2024 Financial Results Q2 2024 OvaSuiteSM revenue of $2.4 million and volume of 6,471 units Q2 2024 cash utilization decreased by 16% compared to Q1 2024 Full year 2024 cash guidance decreased to $13-$14.5 million Conference Call and Webcast scheduled for today at 4:30 pm ET AUSTIN, Texas, August 12, 2024 (GLOBE NEWSWIRE) -- Aspira Women's Health Inc. ("Aspira" or the "Company") (Nasdaq: AWH), a bio-analytical based women's health company focused on the developme ...

Financial Performance - In Q2 2024, Aspira Women's Health Inc. reported revenue of $2.4 million, a slight decrease from $2.5 million in Q2 2023, with approximately 6,471 OvaSuite tests performed, representing a 3% increase year-over-year [5] - The average unit price for OvaSuite tests was $374 in Q2 2024, down from $396 in Q2 2023 [5] - Gross profit margin for Q2 2024 was 59%, compared to 62% in the same period last year, impacted by increased shipping costs [6] - Research and development expenses rose by 37% to $1.0 million in Q2 2024, while sales and marketing expenses increased by 21% to $2.1 million [7] - General and administrative expenses decreased by 20% to $2.7 million in Q2 2024 [7] Cash Utilization and Guidance - Cash utilization decreased by 16% in Q2 2024 compared to Q1 2024 [1] - The full-year cash guidance for 2024 has been revised down to $13-$14.5 million from an earlier estimate of $15-$18 million [1][8] Market Expansion and Product Development - OvaWatch product volume grew by 48% in Q2 2024 compared to the previous year, indicating strong future growth potential [2] - The addressable market for the commercial portfolio has expanded to between 2 and 4 million tests per year, significantly larger than the Ova1Plus test's current market share of 5-10% [2] - The company is focused on developing molecular tests for ovarian cancer and endometriosis, which are expected to be groundbreaking for women's health [2] Corporate Developments - Aspira appointed John Ragard to its Board of Directors, bringing extensive experience in managing billion-dollar portfolios [3] - The company closed a private placement for gross proceeds of $1.9 million and completed a warrant exercise transaction for $2.1 million in July 2024 [4] - John Kallassy has been appointed as interim chief financial officer, effective August 15, 2024 [4] Conference Call - A conference call and webcast are scheduled for today at 4:30 pm ET to discuss the financial results and future outlook [1][9]